ABSTRACT
Objective:
Osteoporosis (OP) is a skeletal disease characterised by low bone mass, which may occur due to primary or secondary reasons, and is known to increase the risk of fracture. The present study aimed to investigate the frequency and reasons for the diagnosis of secondary OP in patients presenting to our clinic and its relationship with fracture.
Materials and Methods:
Medical records of patients who came to our outpatient clinic with OP diagnosis were retrospectively reviewed. Demographic data (age, sex, etc.), comorbidities, drugs and fracture history of patients with secondary OP were obtained from the file information.
Results:
A total of 2,199 patients with OP were reviewed and 341 patients with secondary OP were included in the study. The most common causes of secondary OP were malignancy (38.4%), drug use (24.6%), rheumatologic diseases (17.3%). In addition, 94 patients had fractures and the mean age of these patients was statistically higher than those without fractures (p=0.008). Furthermore, the fracture rate was significantly higher in patients with chronic renal failure (CRF) (p= 0.034) and parathyroid adenoma (p=0.031) than those without these conditions.
Conclusion:
Causes of secondary OP and fracture rates were determined in patients with OP. Age was associated with CRF and parathyroid adenoma fracture rates. These situations should not be ignored while evaluating patients.
References
1WHO Scientific Group on the Prevention and Management of Osteoporosis. Prevention and management of osteoporosis: report of a WHO scientific group. Technical Report Series 921. Geneva: World Health Organization; 2003.
2Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med 2008;358:1474-82.
3Liao CY, Chung CH, Chu P, Wei KY, Feng TM, Lin FH, et al. Increased risk of osteoporosis in patients with primary biliary cirrhosis. PLoS One 2018;13:e0194418.
4Drake MT. Osteoporosis and cancer. Curr Osteoporos Rep 2013;11:163-70.
5Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO Clinical Practice Guideline. J Clin Oncol 2019;37:2916-46.
6Guise TA. Bone loss and fracture risk associated with cancer therapy. Oncologist 2006;11:1121-31.
7Handforth C, D’Oronzo S, Coleman R, Brown J. Cancer treatment and bone health. Calcif Tissue Int 2018;102:251-64.
8Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects:new evidence defining etiology and strategies for management. Breast Cancer Res 2011;13:205.
9Davidge Pitts CJ, Kearns AE. Update on medications with adverse skeletal effects. Mayo Clin Proc 2011;86:338-43.
10Hong AR, Kim JH, Lee KH, Kim TY, Im SA, Kim TY, et al. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer. Osteoporos Int 2017;28:1413-22.
11Ryan AM, Power DG, Daly L, Cushen SJ, Bhuachalla EN, Prado CM. Cancer-associated malnutrition, cachexia and sarcopenia: The skeleton in the hospital closet 40 years later. Proc Nutr Soc 2016;75:199-211.
12Cağlayan A, Gümüşel BK, Başaran N. Secondary osteoporosis ınduced by hormonal therapy and treatment approaches:Review. Turkiye Klinikleri J Pharm Sci 2013;2:74-84.
13Berkit IK, Turan Y, Şendur OF. Steroid Induced Osteoporosis. Turk J Osteoporos 2009;15:83-8.
14Uygur MM, Yavuz DG. Glukokortikoid Osteoporozu. Turkiye Klinikleri J Endocrin-Special Topics 2017;10:111-6.
15Benlidayı IC. Denosumab in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 2018;38:1975-84.
16Pennisi P, Trombetti A, Rizzoli R. Glucocorticoid-induced osteoporosis and its treatment. Clin Orthop Relat Res 2006;443:39-47.
17Kim SM, Kim KM, Kim BT, Joo NS, Kim KN, Lee DJ. Correlation of undercarboxylated osteocalcin (ucOC) concentration and bone density with age in healthy Korean women. J Korean Med Sci 2010;25:1171-5.
18Misra D, Zhang Y, Peloquin C, Choi HK, Kiel DP, Neogi T. Incident long-term warfarin use and risk of osteoporotic fractures: Propensity-score matched cohort of elders with new onset atrial fibrillation. Osteoporos Int 2014;25:1677-84.
19Gielen E, Vanderschueren D, Callewaert F, Boonen S. Osteoporosis in men. Best Pract Res Clin Endocrinol Metab 2011;25:321-35.
20Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, et al. TSH is a negative regulator of skeletal remodeling. Cell 2003;115:151-62.
21van Rijn LE, Pop VJ, Williams GR. Low bone mineral density is related to high physiological levels of free thyroxine in peri-menopausal women. Eur J Endocrinol 2014;170:461-8.
22Hoes JN, Bultink IE, Lems WF. Management of osteoporosis in rheumatoid arthritis patients. Expert Opin Pharmacother 2015;16:559-71.
23Sapir-Koren R, Livshits G. Postmenopausal osteoporosis in rheumatoid arthritis: The estrogen deficiency-immune mechanisms link. Bone 2017;103:102-15.
24Suzuki T, Nakamura Y, Kato H. Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis. Ther Clin Risk Manag 2018;15:15-22.
25Tomizawa T, Ito H, Murata K, Hashimoto M, Tanaka M, Murakami K, et al. Distinct biomarkers for different bones in osteoporosis with rheumatoid arth ritis. Arthritis Res Ther 2019;21:174.
26Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med 2009;122:599-604.
27Shah-Khan SM, Cumberledge J, Shah-Khan SM, Gannon K, Kupec JT. Improving bone mineral density screening in patients with inflammatory bowel disease: a quality improvement report. BMJ Open Qual 2019:19;8:e000624.
28Schüle S, Rossel J-B, Frey D, Biedermann L, Scharl M, Zeitz J, et al. Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study. Medicine 2017;96:e6788
29Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C, et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 2012;23:2239-56.
30Liu Y, Wang Z, Xiao W. Risk factors for mortality in elderly patients with hip fractures: a meta-analysis of 18 studies. Aging Clin Exp Res 2018;30:323-30.
31Cui Z, Feng H, Meng X, Zhuang S, Liu Z, Ye K, et al. Age-specific 1-year mortality rates after hip fracture based on the populations in mainland China between the years 2000 and 2018: a systematic analysis. Arch Osteoporos 2019;14:55.
32Ulusoylar N, Günay FS, Dokuzlar Ö, Okudur SK. The frequency of fall in Geriatric Syndromes. J Geriatr Sci 2019;2:8-13.
33Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Senocak M, Johansson H, et al. Incidence of fracture and prevalance of osteoporosis in Turkey: the FRACTURK study. Osteoporos Int 2012;23:949-55.
34Akgün K. Erkek osteoporoz. Turkiye Klinikleri J PM&R-Special Topics 2012;5:66-72.
35Lips P, Goldsmith D, de Jongh R. Vitamin D and osteoporosis in chronic kidney disease. J Nephrol 2017;30:671-5.
36Khairallah P, Nickolas TL. Management of osteoporosis in CKD. Clin J Am Soc Nephrol 2018;13:962-9.
37Bezerra de Carvalho KS, Vasco RFV, Custodio MR, Jorgetti V Moysés RMA, Elias RM. Chronic kidney disease is associated with low BMD at the hip but not at the spine. Osteoporos Int 2019;30:1015-23.
38Zanocco KA, Yeh MW. Primary Hyperparathyroidism: Effects on bone health. Endocrinol Metab Clin North Am 2017;46:87-104.
39Vu TD, Wang XF, Wang Q, Cusano NE, Irani D, Silva BC, et al. New insights into the effects of primary hyperparathyroidism on the cortical and trabecular compartments of bone. Bone 2013;55:57-63.
40Dhanwal DK, Sahoo S, Gautam VK, Saha R. Hip fracture patients in India have vitamin D deficiency and secondary hyperparathyroidism. Osteoporos Int 2013;24:553-57.
41Rejnmark L, Vestergaard P, Brot C, Mosekilde L. Increased fracture risk in normocalcemic postmenopausal women with high parathyroid hormone levels: a 16-year follow-up study. Calcif Tissue Int 2011;88:238-45.
42Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L, Rejnmark L. Effects of PTH (1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int 2014;25:1717-26.
43Byun SE, Lee S, Kim JW, Ha YC, Kim CH, Ha C, et al. Preventive effects of low parathyroid hormone levels on hip fracture in patients with vitamin D deficiency. J Bone Metab 2019;26:89-95.
